Post Vaccination Study

1. Results from research study will be validated by rapid diagnostic testing

2. Project has a duration of approx. 24 months

28,73,472

IIT Jammu-AIIMS Rishikesh

J&K, Punjab and Delhi

Dr. Karan Nathwani, Dr. Dharitri Rath and Dr. Minakshi Dhar

Submitted to potential donors

Click here for more details

Proposed study - to be conducted over three years - has a strong overlap with the vaccine efficacy study proposed under the Bangalore cluster of IDEA-V

1,50,00,000

IIT-Roorkee, Bio-NEST/TIDES Incubator

Uttarakhand, Delhi and Haryana

Prof. Soma Rohatgi

Exploratory conversation completed

Click here for more details

1. Determination of immunogenicity against COVID-19 in vaccinated individuals

2. Longitudinal serosurveillance of vaccinated individuals to check the sustainability of anti SAR-CoV-2 IgG in recurrent infections

3,96,20,000

Council of Scientific and Industrial Research-North East Institute of Science and Technology (CSIR-NEIST)

Assam, Manipur, Meghalaya, Nagaland, Arunachal Pradesh, Sikkim, Mizoram and Tripura

Director, CSIR-NEIST, Jorhat

Submitted to potential donors

Click here for more details

1. Identify and sample a cohort of individuals post-vaccination for long term impact of the vaccine

2. Identify and sample a cohort of individuals for antibody assessment of convalescent plasma from infected patients 2 months post infection

3. Monitor longitudinally anti-SARS-CoV-2 humoral immune response through qualitative and quantitative assessment of antibodies in the cohort

4. Develop and maintain a cryorepository of post-vaccination and convalescent plasma biological samples for future retrospective analysis

The results can provide valuable inputs for planning further phases of the vaccination campaign, and will also support confidence-building for vaccination. The results will represent the largest post vaccination immune response study so far in the country. The implementation of this program will thus result in a significant milestone in the delineating the antibody response to SARS-CoV2 in India and its application to COVID 19 pandemic and human infectious disease. 

5,53,00,000

Pune Knowledge Cluster (PKC)

Pune (with a network of 70 hospitals and the Pune Municipal Corporation)

Dr Anu Raghunathan and Prof LS Shashidhara

Under review

Click here for more details

Project will aim to address the possibility of adverse neurological events associated with administration of the adenoviral as well as inactivated coronavirus vaccines in India

30,00,000

IISER Tirupati

Tirupati (in collaboration with SVIMS Hospital, Tirupati)

Vasudharani Devanathan

Submitted to potential donors

Click here for more details